Treatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis.

Abstract

ANCA vasculitis is a small-vessel vasculitis (SVV) resulting in inflammation of small- and medium-sized blood vessels. Since the initial description of SVV, there have been tremendous advances in our understanding of its pathogenesis. Over the last decade, we have made significant progress in understanding the pathogenesis and improving the treatment and prognosis of patients with ANCA vasculitis. Patient and renal survival has improved, and treatment is moving toward individualizing care, minimizing severe adverse events, and preventing relapse. This review focuses on treatment updates in ANCA vasculitis, duration of therapy, and management of relapses. We also describe the existing treatment protocols used at our institution.

• Authors: Koyal Jain, Pankaj Jawa, Vimal K Derebail, Ronald J Falk
• Journal: Kidney360 (Kidney360) Vol. 2 Issue 4 Pg. 763-770 (04 2021) ISSN: 2641-7650 [Electronic] United States
• PMID: 34095854 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Antibodies, Antineutrophil Cytoplasmic
• Autoantibodies

Topics

• Antibodies, Antineutrophil Cytoplasmic
• Autoantibodies
• Humans
• Kidney (pathology)
• Recurrence
• Vasculitis (etiology)